Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

New Labor Ads Focus On Health Benefits Tax
"Much of the TV advertising on health care so far has focused on the controversial public, or government-run insurance program that Democrats say would compete with private insurers and Republicans say would drive them out of business," but the Laborers" International Union of North America "will begin airing ads in two states Tuesday that deal with an equally explosive issue: Taxing health benefits," USA Today reports. The union will "run the ads at least through Thursday in North Dakota and Montana," home states of "the two most important senators on the issue, Senate Finance Chairman Max Baucus, D-Mont., and Senate Budget Committee Chairman Kent Conrad, D-N.D." The ads reveal the "fine line labor is walking" on health care: "The ads first praise Congress for taking up the health care debate but then criticize an idea that could be included in one draft of the legislation to tax health care premiums" (Fritze, 6/29).
generic viagra online
Cubist Pharmaceuticals Initiates Phase 2 Trial In Europe For Therapy To Reduce Blood Loss During Surgery In High Risk Patients
Cubist Pharmaceuticals, Inc. (Nasdaq: CBST), a leading acute care therapeutics company, announced that it has begun dosing in the CONSERV™-2 clinical trial with ecallantide. CONSERV-2, being conducted in Europe, is a Phase 2 trial that will investigate ecallantide"s effect on surgical blood loss volume in cardiac surgery patients who are on cardiopulmonary bypass and are at a high risk of bleeding. The trial is expected to enroll 300 subjects.
News of the day
Catastrophic Sports Injury Report Released
The National Center for Catastrophic Sports Injury Research based at the University of North Carolina at Chapel Hill has released its 26th annual all sports report.
Cardiovascular

"Artificial Golgi" May Provide New Insight Into Key Cell Structure

Scientists in New York and North Carolina are reporting assembly of the first functioning prototype of an artificial Golgi organelle. That key structure inside cells helps process and package hormones, enzymes, and other substances that allow the body to function normally. The lab-on-a-chip device could lead to a faster and safer method for producing heparin, the widely used anticoagulant or blood thinner, the researchers note. Their study is scheduled for the Aug. 12 issue of the Journal of the American Chemical Society, a weekly publication. The Golgi organelle is named for Camillo Golgi, the Italian scientist and Nobel Prize winner who discovered the structure in 1898. It is composed of a network of sacs, stacked like a deck of playing cards, located inside cells. In the new study, Robert Linhardt and colleagues point out that Golgi bodies are one of the most poorly understood organelles (specialized structures inside cells) in the human body. Scientists already know, however, that the organelles play a key role in producing heparin, a substance that helps prevent clotting. The researchers describe development of a prototype lab-on-a-chip device that closely mimics the natural Golgi apparatus. They showed in lab tests that the device could quickly and efficiently produce heparin. It did so in an assembly-line fashion using a combination of enzymes, sugars and other raw materials and demonstrated that the substance has a strong clot-fighting potential. In the future, an "artificial Golgi" could lead to a faster and safer method for producing heparin, the scientists suggest. Journal of the American Chemical Society


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009